Echocardiography is a valuable tool for characterizing cardiovascular phenotypes in rodent models and assessing preclinical drug toxicity.
Echocardiography may enhance preclinical cardiotoxicity screening; leaves open standardization and prospective validation before broader adoption.
Echocardiographic techniques are commonly utilized to describe the rodent cardiovascular phenotype. These approaches are contrasted with other in vivo methods and are positioned in the assay selection process by a review of studies from our laboratory and others. Although not conventionally considered a biomarker, the technique has the potential to be exploited as a marker of intentional or unanticipated toxic biological effects in the preclinical development of drugs and chemicals.
No takes yet. Share an insight, caveat, or question.
Brian D. Hoit (2006) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: